Deutsche Bank
ADMS

Deutsche Bank’s Adamas Pharmaceuticals ADMS Stock Holding History

Deutsche Bank’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,620
Closed -$72K – 4781
2021
Q2 		$72K Sell
13,620
-23,600
-63% -$122K ﹤0.01% 4237
2021
Q1 		$179K Sell
37,220
-317,859
-90% -$1.66M ﹤0.01% 3696
2020
Q4 		$1.54M Buy
355,079
+316,859
+829% +$1.36M ﹤0.01% 2117
2020
Q3 		$157K Buy
38,220
+17,935
+88% +$69.4K ﹤0.01% 3342
2020
Q2 		$52K Sell
20,285
-5,131
-20% -$15.1K ﹤0.01% 3808
2020
Q1 		$73K Sell
25,416
-66,562
-72% -$298K ﹤0.01% 3382
2019
Q4 		$348K Sell
91,978
-80,700
-47% -$386K ﹤0.01% 2915
2019
Q3 		$883K Sell
172,678
-81,800
-32% -$505K ﹤0.01% 2372
2019
Q2 		$1.58M Buy
254,478
+227,548
+845% +$1.31M ﹤0.01% 2553
2019
Q1 		$190K Sell
26,930
-247,120
-90% -$2.22M ﹤0.01% 4031
2018
Q4 		$2.34M Buy
274,050
+134,129
+96% +$1.74M ﹤0.01% 2296
2018
Q3 		$2.8M Buy
139,921
+89,731
+179% +$2.11M ﹤0.01% 2635
2018
Q2 		$1.3M Sell
50,190
-138,443
-73% -$3.83M ﹤0.01% 3248
2018
Q1 		$4.51M Sell
188,633
-317,736
-63% -$10M ﹤0.01% 2306
2017
Q4 		$17.2M Buy
506,369
+437,263
+633% +$12.2M 0.01% 1107
2017
Q3 		$1.46M Buy
69,106
+51,008
+282% +$935K ﹤0.01% 2753
2017
Q2 		$315K Buy
18,098
+12,982
+254% +$215K ﹤0.01% 3694
2017
Q1 		$88K Sell
5,116
-5,182
-50% -$88.3K ﹤0.01% 3975
2016
Q4 		$172K Buy
10,298
+5,251
+104% +$81.2K ﹤0.01% 3772
2016
Q3 		$82K Sell
5,047
-24,037
-83% -$365K ﹤0.01% 4014
2016
Q2 		$439K Sell
29,084
-30,681
-51% -$506K ﹤0.01% 3364
2016
Q1 		$863K Buy
59,765
+53,447
+846% +$900K ﹤0.01% 2905
2015
Q4 		$177K Sell
6,318
-91,081
-94% -$1.53M ﹤0.01% 3782
2015
Q3 		$1.63M Buy
97,399
+25,753
+36% +$586K ﹤0.01% 2624
2015
Q2 		$1.88M Buy
71,646
+71,645
+7,164,500% +$1.39M ﹤0.01% 2501
2015
Q1 		$0 Sell
1
-12,134
-100% -$208K ﹤0.01% 6167
2014
Q4 		$210K Buy
12,135
+8,187
+207% +$124K ﹤0.01% 4275
2014
Q3 		$73K Sell
3,948
-6,486
-62% -$112K ﹤0.01% 4666
2014
Q2 		$190K Buy
+10,434
New +$187K ﹤0.01% 4159

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank's ADMS Position: Q3 2021 in Review

Deutsche Bank sold out of Adamas Pharmaceuticals (ADMS) in Q3 2021, closing a stake of 13,620 shares — an estimated $72K sold.

Deutsche Bank first reported a position in ADMS in Q2 2014 and held it in 29 quarters. The position peaked at $17.2M in Q4 2017. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2021.

  • Deutsche Bank reported no remaining Adamas Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Deutsche Bank sold 13,620 Adamas Pharmaceuticals shares in Q3 2021, an estimated $72K.
  • Deutsche Bank first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 29 quarters.
  • Deutsche Bank's Adamas Pharmaceuticals position peaked at $17.2M in Q4 2017.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2021.

Based on Deutsche Bank's 13F filing for Q3 2021, filed 4 Nov 2021.